Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Intellia Therapeutics
Biotech
Intellia doesn't need to re-dose NTLA-2001. But it can be done
Intellia Therapeutics doesn’t need to redose patients with a CRISPR gene edited therapy for ATTR amyloidosis. But new data suggests it could be done.
Annalee Armstrong
Jun 25, 2024 3:31pm
Intellia showcases durability of one-and-done HAE option
Jun 2, 2024 8:00am
Intellia opts out of hemophilia gene editing work with Regeneron
Mar 22, 2024 11:21am
KalVista's persistence with sebetralstat pays off in ph. 3 win
Feb 13, 2024 6:30am
JPM24, Day 3: Gene editors talk BD; Roivant has cash to spend
Jan 10, 2024 4:38pm
Intellia, Aera the latest gene editing biotechs to lay off staff
Jan 4, 2024 6:50pm
